Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Conditions
Interventions
Cyclophosphamide
Doxorubicin
+9 more
Locations
107
United States
Maryland Oncology Hematology
Rockville, Maryland, United States
San Juan Oncology Associates
Farmington, New Mexico, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Northwest Medical Specialties
Lakewood, Washington, United States
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina
Start Date
June 14, 2018
Primary Completion Date
July 4, 2019
Completion Date
June 2, 2023
Last Updated
June 26, 2024
NCT07379918
NCT06797531
NCT07331506
NCT07007169
NCT07071402
NCT06928701
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions